Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Altamira Therapeutics (CYTOF) Stock Price & Analysis

600 Followers

CYTOF Stock Chart & Stats

$0.07$0.00(-2.78%)
At close: 4:00 PM EST
$0.05$0.075$0.1Aug 18Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.07 - $0.07
52-Week Range
$0.05 - $0.15
Previous Close
$0.07
Volume
N/A
Average Volume (3M)
4,417
Market Cap
$404.65K
Enterprise Value
$1.95M
Total Cash (Recent Filing)
$49.57K
Total Debt (Recent Filing)
$3.47M
Price to Earnings (P/E)
―
Beta
1.88
Next Earnings
Apr 14, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Equity Improvement

The improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth initiatives.

Proprietary Technology Platforms

Proprietary technology platforms can provide a competitive edge in the biotechnology sector, enabling the development of unique treatments and potential market leadership.

Strategic Alliances

Strategic alliances and collaborations can enhance Altamira's research capabilities, provide financial support, and accelerate the development and commercialization of its therapies.

Bears Say

Negative Cash Flow

Persistent negative cash flow can strain the company's liquidity, limiting its ability to invest in growth opportunities and potentially necessitating additional funding.

Declining Revenue

Declining revenue trends suggest challenges in product adoption or market penetration, which could hinder long-term growth and profitability prospects.

Operational Inefficiencies

Operational inefficiencies and negative profit margins indicate challenges in cost management, which can impact the company's ability to achieve sustainable profitability.

Altamira Therapeutics News

CYTOF FAQ

What was Altamira Therapeutics’s price range in the past 12 months?
Altamira Therapeutics lowest stock price was $0.05 and its highest was $0.15 in the past 12 months.
What is Altamira Therapeutics’s market cap?
Altamira Therapeutics’s market cap is $404.65K.
When is Altamira Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Altamira Therapeutics’s earnings last quarter?
Altamira Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.246 earnings per share for the quarter.
Is Altamira Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Altamira Therapeutics pay dividends?
Altamira Therapeutics does not currently pay dividends.
What is Altamira Therapeutics’s EPS estimate?
Altamira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Altamira Therapeutics have?
Altamira Therapeutics has 5,715,472 shares outstanding.
What happened to Altamira Therapeutics’s price movement after its last earnings report?
Altamira Therapeutics reported an EPS of -$0.246 in its last earnings report. Following the earnings report the stock price went down -4.11%.
Which hedge fund is a major shareholder of Altamira Therapeutics?
Currently, no hedge funds are holding shares in CYTOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology